Table 8.
Summary of measured amyloid-β 1–42 peptide concentrations for samples from study I4O-MC-BACA (n = 48) using both Quanterix and Fujirebio amyloid-β 1–42 peptides for calibration
| Aβ1–42 (pg/ml) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Quanterix Aβ1–42 peptide calibration | Fujirebio Aβ1–42 peptide calibration | ||||||||
| Subject | Dose | 0 h | 1 h | 6 h | 12 h | 0 h | 1 h | 6 h | 12 h |
| A | Placebo | 16.8 | 16.9 | 17.0 | 18.1 | 39.7 | 39.9 | 40.0 | 42.9 |
| D | Placebo | 14.7 | 13.3 | 10.9 | 12.0 | 34.4 | 31.1 | 25.1 | 27.8 |
| G | Placebo | 18.6 | 18.8 | 18.3 | 20.8 | 43.9 | 44.6 | 43.3 | 49.4 |
| B | 7 mg | 18.7 | 12.2 | 8.03 | 8.25 | 44.3 | 28.3 | 17.9 | 18.5 |
| C | 7 mg | 21.0 | 19.6 | 7.64 | 6.70 | 49.9 | 46.4 | 17.0 | 14.6 |
| E | 7 mg | 20.4 | 22.8 | 9.48 | 12.0 | 48.4 | 54.2 | 21.5 | 27.9 |
| A | 15 mg | 16.9 | 13.1 | 5.65 | 6.61 | 39.8 | 30.6 | 11.9 | 14.3 |
| F | 15 mg | 17.4 | 14.4 | 5.99 | 5.74 | 41.1 | 33.7 | 12.8 | 12.1 |
| K | 15 mg | 20.5 | 14.2 | 6.51 | 5.95 | 48.8 | 33.3 | 14.1 | 12.7 |
| H | 35 mg | 21.7 | 16.8 | 4.80 | 4.88 | 51.5 | 39.7 | 9.74 | 9.94 |
| I | 35 mg | 18.6 | 15.5 | 7.43 | 5.27 | 44.1 | 36.4 | 16.4 | 11.0 |
| J | 35 mg | 19.5 | 19.1 | 6.92 | 4.56 | 46.3 | 45.2 | 15.1 | 9.12 |
Aβ amyloid-β